Get an Early Assessment of Immunogenicity of Biologics
Benefits of Early Immunogenicity Assessment
Assessing the response of the immune system to different therapies, such as drugs, vaccines, and other biologics, is an important step at various points of a drug development program.
When performed at the discovery and pre-clinical phase, assessment of unwanted immunogenicity allows for the selection of candidates with the lowest immunogenic potential.
This also provides data to support the re-engineering of biologics and adaptation of the formulation.
Leveraging its unique and long-standing expertise in mass spectrometry, CellCarta offers MHC-Associated Peptide Proteomics (MAPPs) services to identify presented peptides with potential adverse immunogenicity.
Exploring Immunogenicity with MHC-Associated Peptide Proteomics (MAPPs)
MAPPs services provide direct empirical data reflecting the whole peptide presentation process and complementing in silico prediction approaches.
It is the closest representation of the in vivo situation using human cells, as it reflects the antigen processing and presentation steps of the process.
As an empirical approach, MAPPs allow us to assess the potential impact of protein aggregation or post-translational modification on immunogenicity.
It is also well-suited to study drugs such as immune checkpoint inhibitors that are designed to interfere with the T-cell response and are difficult to study using in vitro T-cell assays.
At CellCarta, we have years of experience in processing loaded antigen-presenting cells and identifying presented antigens by proteomic analysis.
Peptide sequences derived from the tested proteins and presented by MHC II on antigen-presenting cells are isolated and identified using a combination of mass spectrometry and bioinformatics analysis.
Results are provided in an easy-to-interpret format, including annotated cluster maps of presented peptides regions.
Interested to learn more about this service?
